Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 132 av 132 resultater
Tid
Selskap
Tittel
Sektor
Kategori
17 Dec 2021
07:15 CET
GENFIT
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset
20103010 Biotechnology
Other subject
17 Dec 2021
07:15 CET
GENFIT
GENFIT : A la suite du partenariat stratégique global annoncé ce jour, GENFIT acquiert les droits pour un nouveau composé
20103010 Biotechnology
Other subject
17 Dec 2021
07:00 CET
GENFIT
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
20103010 Biotechnology
Other subject
17 Dec 2021
07:00 CET
GENFIT
GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long terme
20103010 Biotechnology
Other subject
18 Nov 2021
22:15 CET
GENFIT
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH
20103010 Biotechnology
Other subject
18 Nov 2021
22:15 CET
GENFIT
GENFIT : Une étude menée par FNIH NIMBLE démontre la performance unique de la technologie NIS4® pour identifier les patients atteints d’une NASH « à risque »
20103010 Biotechnology
Other subject
09 Nov 2021
22:10 CET
GENFIT
GENFIT : première consultation du premier patient pour l’évaluation de NTZ chez des sujets présentant une dysfonction hépatique dans le cadre du programme ACLF
20103010 Biotechnology
Other subject
09 Nov 2021
22:10 CET
GENFIT
GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program
20103010 Biotechnology
Other subject
08 Nov 2021
22:10 CET
GENFIT
GENFIT : Information financière du troisième trimestre 2021
20103010 Biotechnology
Other subject
08 Nov 2021
22:10 CET
GENFIT
GENFIT: Third Quarter 2021 Financial Information
20103010 Biotechnology
Other subject
02 Nov 2021
22:10 CET
GENFIT
GENFIT : Nouvelles données cliniques concernant son composé expérimental elafibranor présentées à l’AASLD The Liver Meeting®
20103010 Biotechnology
Other subject
02 Nov 2021
22:10 CET
GENFIT
New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®
20103010 Biotechnology
Other subject
29 Sep 2021
22:10 CEST
GENFIT
GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update
20103010 Biotechnology
Other subject
29 Sep 2021
22:10 CEST
GENFIT
Genfit : Résultats financiers du premier semestre 2021 et point sur les activités de la Société
20103010 Biotechnology
Other subject
09 Jul 2021
22:10 CEST
GENFIT
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
09 Jul 2021
22:10 CEST
GENFIT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
30 Jun 2021
22:10 CEST
GENFIT
GENFIT: June 30, 2021 Annual Shareholders Meeting results
20103010 Biotechnology
General meeting / Board Meeting
30 Jun 2021
22:10 CEST
GENFIT
GENFIT : Résultats de l’Assemblée Générale Mixte du 30 juin 2021
20103010 Biotechnology
General meeting / Board Meeting
24 Jun 2021
22:10 CEST
GENFIT
GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan
20103010 Biotechnology
Other subject
24 Jun 2021
22:10 CEST
GENFIT
GENFIT obtient un financement non dilutif de 11 millions d’euros sous forme de Prêt Garanti par l’Etat
20103010 Biotechnology
Other subject
23 Jun 2021
22:10 CEST
GENFIT
GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association
20103010 Biotechnology
Other subject
23 Jun 2021
22:10 CEST
GENFIT
GENFIT présente de nouvelles données sur NIS4® dans la NASH à l’International Liver Congress™ ainsi qu’aux 81èmes « Scientific Sessions » de l’American Diabetes Association
20103010 Biotechnology
Other subject
15 Jun 2021
22:10 CEST
GENFIT
GENFIT : Assemblée Générale Mixte du 15 juin 2021 : Soutien largement majoritaire à ce stade pour les résolutions soumises à l’approbation des actionnaires, mais quorum insuffisant sur première convocation
20103010 Biotechnology
General meeting / Board Meeting
15 Jun 2021
22:10 CEST
GENFIT
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening
20103010 Biotechnology
General meeting / Board Meeting
27 May 2021
22:10 CEST
GENFIT
GENFIT informe ses actionnaires sur certaines modalités de l’Assemblée Générale Mixte du 15 juin 2021
20103010 Biotechnology
General meeting / Board Meeting
27 May 2021
22:10 CEST
GENFIT
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
20103010 Biotechnology
General meeting / Board Meeting
12 May 2021
22:10 CEST
GENFIT
GENFIT : Information financière du premier trimestre 2021
20103010 Biotechnology
Sales
12 May 2021
22:10 CEST
GENFIT
GENFIT: Reports First Quarter 2021 Financial Information
20103010 Biotechnology
Sales
11 May 2021
22:10 CEST
GENFIT
GENFIT Provides Pipeline Update and Launch of New Clinical Programs
20103010 Biotechnology
Other subject
11 May 2021
22:10 CEST
GENFIT
GENFIT : mise à jour du portefeuille de produits et lancement de nouveaux programmes cliniques
20103010 Biotechnology
Other subject
10 May 2021
22:10 CEST
GENFIT
GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents
20103010 Biotechnology
General meeting / Board Meeting
10 May 2021
22:10 CEST
GENFIT
GENFIT : Assemblée Générale Mixte du 15 juin 2021 - modalités de mise à disposition des documents préparatoires
20103010 Biotechnology
General meeting / Board Meeting
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva